P025: Colonic rather than ileal expression of ITGA4/ITGB7 correlates with local intestinal inflammation in IBDECCO’23 CopenhagenYear: 2023
Authors: Csomor, E.(1)*;Gehrmann, U.(2);Monkley, S.(2);Tian, S.(1);Cairns, J.(2);Angermann, B.(2);Khan, E.(3);Nys, J.(4);Marks, D.(5);
(1)AstraZeneca, Translational Science & Experimental Medicine- Research and Early Development- Respiratory and Immunology R&I, Cambridge, United Kingdom;(2)AstraZeneca, Translational Science & Experimental Medicine- Research and Early Development- Respiratory and Immunology R&I, Gothenburg, Sweden;(3)AstraZeneca, Late Clinical Development- Respiratory and Immunology R&I, Cambridge, United Kingdom;(4)AstraZeneca, Bioscience Asthma- Research and Early Development- Respiratory and Immunology R&I, Cambridge, United Kingdom;(5)AstraZeneca, Early Clinical Development- Respiratory and Immunology R&I, Cambridge, United Kingdom;
P026: Cost per Response/Remission analysis of biologic therapies availables in Argentina for the treatment of Bio-exposed patients with moderate-to-severe active Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Elgart, J.(1);Balderramo, S.(2);Calvi, G.(3);Kanevsky, D.(3);Sánchez Gonzalez, Y.(4)*;
(1)CENEXA. Center of Experimental and Applied Endocrinology, Health Economics, La Plata, Argentina;(2)Hospital Privado Universitario de Cordoba, Gastroenterology Department, Cordoba, Argentina;(3)AbbVie Argentina, Market Access, Buenos Aires, Argentina;(4)AbbVie Inc., HEOR Strategy – Ulcerative Colitis, Chicago, United States;
P027: Anorectal Motility Disorders in Inflammatory Bowel Disease patientsECCO’23 CopenhagenYear: 2023
Authors: Costache, R.(1)*;Dimitriu, A.(1,2);Les, A.(1);Gheorghe, C.(1,2);
(1)Fundeni Clinical Institute, Gastroenterology and Hepatology, Bucharest, Romania;(2)“Carol-Davila” University of Medicine and Pharmacy, Gastroenterology, Bucharest, Romania;
P028: Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease – what is the opportunity cost of improving access to health care?ECCO’23 CopenhagenYear: 2023
Authors: Hilley, P.(1,2)*;Wong, D.(1,3);Ma, R.(4);Peterson, A.(1);De Cruz, P.(1,3);
(1)AUSTIN HEALTH, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Melbourne Academic Centre for Health, Melbourne, Australia;(3)University of Melbourne, Department of Medicine- Austin Academic Centre, Melbourne, Australia;(4)Austin Health, Business Intelligence Unit, Melbourne, Australia;
P029: Histopathological characterization of a chronic DSS-induced mouse model of IBD with intestinal fibrosisECCO’23 CopenhagenYear: 2023
Authors: Nielsen, M.H.(1)*;Zachariassen, L.F.(1);Sárvári, A.K.(2);Marstrand-Jørgensen, A.B.(3);Hansen, H.H.(4);Feigh, M.(4);
(1)Gubra, In vivo pharmacology, Hørsholm, Denmark;(2)Gubra, Tissue research, Hørsholm, Denmark;(3)Gubra, Assay & NGS, Hørsholm, Denmark;(4)Gubra, Sales & Marketing, Hørsholm, Denmark;
P031: CKD-506, a new histone deacetylase 6 inhibitor, suppresses immune cells and restores intestinal epithelial functionECCO’23 CopenhagenYear: 2023
Authors: Lee, J.Y.(1);Ma, H.W.(2);Kim, J.H.(2);Park, I.S.(2);Son, M.(2);Ryu, K.H.(3);Shin, J.(3);Kim, W.H.(4);KimResearch professor, S.W.(2)*;Cheon, J.H.(4);
(1)Yonsei University College of Medicine, Department of Medicine, Seoul, Korea- Republic Of;(2)Yonsei University College of Medicine, Graduate School of Medical Science, Seoul, Korea- Republic Of;(3)CKD Pharmaceutical Co., Non-clinical Study, Yongin, Korea- Republic Of;(4)Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea- Republic Of;
P032: Distinct immune cell trigger responses in Ulcerative Colitis – Results from an in vivo human intestinal injury modelECCO’23 CopenhagenYear: 2023
Authors: Bronze, M.(1,2)*;Vilstrup Johansen, J.(3);Attauabi, M.(1);Tveiten Bjerrum, J.(1);Ramírez Galera, M.(2);Woetmann, A.(2);Benedict Seidelin, J.(1);
(1)Herlev and Gentofte Hospital, Department of Gastroenterology and Hepatology, Herlev, Denmark;(2)University of Copenhagen, Department of Immunology and Microbiology, Copenhagen, Denmark;(3)University of Copenhagen, BRIC Bioinformatics Core Facility, Copenhagen, Denmark;
P033: The assessment of serum cytokines at baseline could predict mucosal healing in patients with Crohn's disease treated with ustekinumab. A prospective study.ECCO’23 CopenhagenYear: 2023
Authors: BertaniMD, L.(1)*;Antonioli, L.(2);Fornili, M.(2);D'Antongiovanni, V.(2);Coppini, F.(1);Ceccarelli, L.(3);Carmisciano, L.(2);Benvenuti, L.(2);Mumolo, M.G.(3);Bottari, A.(1);Baglietto, L.(2);Bellini, M.(1);Fornai, M.(2);De Bortoli, N.(1);Costa, F.(3);
(1)University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy;(2)University of Pisa, Clinical and Experimental Medicine, Pisa, Italy;(3)Pisa University Hospital, General Surgery and Gastroenterology, Pisa, Italy;
P034: A common IL2RA polymorphism alters natural killer cell immunophenotype and function in Crohn's disease, with implications for IL-2 based therapyECCO’23 CopenhagenYear: 2023
Authors: Clough, J.(1)*;Roberts, L.(2);Goldberg, R.(2);Lord, G.(3);Irving, P.(1);
(1)Guy's and St Thomas' NHS Trust, Gastroenterology, LONDON, United Kingdom;(2)King's College London, School of Immunology and Microbial Sciences, London, United Kingdom;(3)University of Manchester, Department of Medicine and Life Sciences, Manchester, United Kingdom;
P035: Anti-inflammatory Effect and Mechanism of Action of BMC333, a Rationally-Designed Live Bacterial Consortium Based on Microbiome Functional Genomic Analysis for Treating IBDECCO’23 CopenhagenYear: 2023
Authors: Tirosh, O.(1);Meshner, S.(1);Eshar, S.(1);Kruger Ben-Shabat, S.(1);Polonski, O.(1);Haber, E.(1);Liu, B.(2);Herzog, J.(2);Sartor, R.B.(2);Ringel, Y.(3)*;
(1)Biomica Ltd., Biomica Ltd., Rehovot, Israel;(2)University of North Carolina, Division of Gastroenterology and Hepatology- Center for Gastrointestinal Biology and Disease, Chapel Hill- NC, United States;(3)Meir Medical Center- affiliated with Tel Aviv University, Division of Gastroenterology and Hepatology, Kfar Saba, Israel;
P036: Analysis of intestinal tissue from newly diagnosed patients with inflammatory bowel disease reveals distinct proteomic profilesECCO’23 CopenhagenYear: 2023
Authors: Baldan-Martin, M.(1)*;Lloro, I.(2);Azkargorta, M.(2);Ramírez, C.(1);Soleto Fernández, I.(1);Orejudo, M.(1);García, S.(1);Mercado, J.(1);Gordillo, C.H.(3);Riestra, S.(4);Rivero, M.(5);Gutiérrez, A.(6);Rodríguez-Lago, I.(7);Fernández-Salazar, L.(8);Ceballos, D.(9);Benítez, J.M.(10);Aguas, M.(11);Bastón-Rey, I.(12);Bermejo, F.(13);Casanova, M.J.(1);Lorente, R.(14);Ber, Y.(15);Royo, V.(16);Esteve, M.(17);Elortza, F.(2);Gisbert, J.P.(1);Chaparro, M.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Proteomics Platform- CIC bioGUNE- BRTA Basque Research & Technology Alliance- CIBERehd- ProteoRed-ISCIII, Proteomics Platform, Derio, Spain;(3)Anatomía patológica- Hospital Universitario de La Princesa., Anatomía patológica, Madrid, Spain;(4)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(5)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain;(6)Hospital General Universitario de Alicante- ISABIAL and CIBERehd, Gastroenterology Unit, Alicante, Spain;(7)Hospital Galdakao-Usansolo, Gastroenterology Unit, Vizcaya, Spain;(8)Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain;(9)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain;(10)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(11)Health Research Institute IISLaFe and Hospital Universitari i Politecnic La Fe, Gastroenterology Unit, Valencia, Spain;(12)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(13)Hospital Universitario de Fuenlabrada and IDIPAZ, Gastroenterology Unit, Madrid, Spain;(14)Hospital General Universitario de Ciudad Real, Gastroenterology Unit, Ciudad Real, Spain;(15)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(16)Hospital Universitari Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(17)Hospital Universitari Mutua Terrasa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Terrasa, Spain;
P037: Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel diseaseECCO’23 CopenhagenYear: 2023
Authors: Moniruzzaman, M.(1,2)*;Rewatkar, P.(1);Begun, J.(2);Popat, A.(1);
(1)The University of Queensland, School of Pharmacy, Brisbane, Australia;(2)The University of Queensland, Mater Research Institute, Brisbane, Australia;
P038: Notch pathway in fibrosis: a new anti-fibrotic therapy in Crohn's disease?ECCO’23 CopenhagenYear: 2023
Authors: Marti-Chafer, S.(1);Jimenez-Mallen, E.(1);Mendoza, T.(1);Macias-Ceja, D.C.(2);Bauset, C.(2)*;Seco-Cervera, M.(3);Calatayud, S.(4);Cosin-Roger, J.(4);Barrachina, M.D.(4);Ortiz-Masiá, D.(5);
(1)Universitat de Valencia, Medicine, Valencia, Spain;(2)Universitat de Valencia, Pharmacology, Valencia, Spain;(3)Universitat de Valencia-FISABIO, Pharmacology, Valencia, Spain;(4)Universitat de Valencia-CIBERehd, Pharmacology, Valencia, Spain;(5)Universitat de Valencia-CIBERehd, Medicine, Valencia, Spain;
P039: The disappearance of cell death brakes in inflammatory bowel disease: a step towards molecular healingECCO’23 CopenhagenYear: 2023
Authors: Al-Ani, A.(1)*;Samson, A.(2);Rickard, J.(3);Christensen, B.(4);Murphy, J.(2);
(1)The Royal Melbourne Hospital Melbourne Health, Gastroenterology, Melbourne, Australia;(2)Walter and Eliza Hall Institute of Medical Research, Inflammation Division, Melbourne, Australia;(3)Royal Melbourne Hospital, Anatomical Pathology, Melbourne, Australia;(4)Royal Melbourne Hospital, Gastroenterology, Melbourne, Australia;
P040: Caspase-8 blockade attenuates NSAID-induced colitis and cell death via NLRP3 inflammasome and NF-κB activationECCO’23 CopenhagenYear: 2023
Authors: Singh, R.(1,2);Rossini, V.(1);Stockdale , S.(1);Draper, L.(1);Hill, C.(1,3);Nally, K.(1,4);Shanahan, F.(1);Andersson-Engels, S.(5,6);MelgarPhD, S.(1)*;
(1)University College Cork, APC Microbiome Ireland, Cork, Ireland;(2)University College Cork, School of Medicine- Department of Medicine-, Cork, Ireland;(3)University College Cork, School of Microbiology, Cork, Ireland;(4)University College Cork, School of Biochemistry and Cell Biology, Cork, Ireland;(5)University College Cork, Department of Physics, Cork, Ireland;(6)Tyndall National Institute, Irish Photonics Integration Centre, Cork, Ireland;
P041: The upregulation of tissue factor in colonic mesenchymal cells in active ulcerative colitis is associated with severe and resistant to treatment disease, but tofacitinib has not effect on itECCO’23 CopenhagenYear: 2023
Authors: Drygiannakis, I.(1)*;Tzenaki, N.(1);Archontoulaki, E.(2);Filidou, E.(3);Kandilogiannakis, L.(3);Valatas, V.(1);Kolios, G.(3);Koutroubakis, I.E.(1);
(1)University of Crete, Gastroenterology Research Laboratory- School of Medicine, Heraklion, Greece;(2)Democritus University of Thrace, Department of Molecular Biology and Genetics- School of Health Sciences, Alexandroupolis, Greece;(3)Democritus University of Thrace, Laboratory of Pharmacology- Department of Medicine- School of Health Sciences, Alexandroupolis, Greece;
P042: Distinct gene expression profile associated to inflammation and neoplastic progression in longstanding ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Alsøe, L.(1);Lefol, Y.(2);Wennerström, A.B.(3);Liu, Y.(3);Andersen, S.N.(4);Klepp, P.(5);Brackmann, S.(6)*;Nilsen, H.(3);
(1)University of Oslo, Department of Clinical Molecular Biology Akershus University Hospital, Nordbyhagen, Norway;(2)University of Oslo, Department of Microbiology, Oslo, Norway;(3)University of Oslo, Department of Clinical Molecular Biology- Akershus University Hospital, Nordbyhagen, Norway;(4)University of Oslo, Department of Pathology- Akershus University Hospital, Nordbyhagen, Norway;(5)Lovisenberg Diakonale Hospital, Medical department, Oslo, Norway;(6)Akershus University Hospital, Department of Gastroenterology, Nordbyhagen, Norway;
P044: Ex vivo effects of infliximab on the long non-coding RNAs expression levels in Crohn´s diseaseECCO’23 CopenhagenYear: 2023
Authors: Baldan-Martin, M.(1)*;Rubín de Célix, C.(1);Orejudo, M.(1);Ortega, L.(2);Fernández-Tomé, S.(1,3);Soleto, I.(1);Ramírez, C.(1);Arroyo, R.(4);Fernández, P.(4);Santander, C.(1);Moreno-Monteagudo, J.A.(1);Casanova, M.J.(1);Casals, F.(1);Casabona, S.(1);Becerro, I.(1);Marigorta, U.M.(5);Aransay, A.M.(6);Bernardo, D.(7);Chaparro, M.(1);Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Área de Farmacología y Nutrición y Bromatología. Departamento Ciencias Básicas de la Salud- Universidad Rey Juan Carlos, Departamento Ciencias Básicas de la Salud, Madrid, Spain;(3)Departamento de Nutrición y Ciencia de los Alimentos- Facultad de Farmacia- Universidad Complutense de Madrid, Departamento de Nutrición y Ciencia de los Alimentos, Madrid, Spain;(4)Instituto de Medicina Molecular Aplicada Nemesio Díez IMMA-ND- Facultad de Medicina. Universidad San Pablo CEU, Instituto de Medicina Molecular Aplicada Nemesio Díez, Madrid, Spain;(5)Integrative Genomics Lab- CIC bioGUNE-BRTA and IKERBASQUE- Basque Foundation for Science, Integrative Genomics Lab, Bilbao, Spain;(6)Genome Analysis Platform- CIC bioGUNE-BRTA and CIBERehd, Genome Analysis Platform, Derio, Spain;(7)Mucosal Immunology Lab- Unidad de Excelencia Instituto de Biomedicina y Genética Molecular IGBM- Universidad de Valladolid-CSIC and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas CIBERINFEC, Mucosal Immunology Lab, Valladolid, Spain;
